ArticleJournal of the Turkish German Gynecological Association2025
Ovarian cancer and isolated cardiophrenic lymph nodes metastases: a systematic review.
Article in Journal of the Turkish German Gynecological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is limited information available on the best course of action for advanced epithelial ovarian cancer (OC) with isolated extra-peritoneal disease in the cardiophrenic lymph nodes. Recently, there have been numerous reports of successful surgical removal of metastatic cardiophrenic lymph nodes in patients with OC, mostly during primary or interval cytoreduction procedures. However, the optimal management of isolated, extra-peritoneal cardiophrenic lymph node metastasis (ICLNM) remains unclear, since this clinical scenario is rather uncommon in OC and chemotherapy is so far the indicated treatment for patients with from advanced stage disease. We searched the English-language literature for cases of OC with ICLNM or recurrence, evaluating the feasibility and safety of surgical excision. From 2009 to 2022 only 11 cases were reported. In seven the tumor was of serous histology. ICLN was detected in five cases with primary disease and in the remaining six it was recurrence of OC. The primary disease was treated in 10/11 patients with primary cytoreduction while the other received systemic chemotherapy. The ICLNM was removed in all the patients, in 10 via video-assisted thoracic surgery and in one via transdiaphragmatic incision. Median follow-up was 10 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.